What is the typical dosage and treatment plan for Macrobid (nitrofurantoin) in treating urinary tract infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Macrobid (Nitrofurantoin) Dosing and Treatment for Urinary Tract Infections

For acute uncomplicated lower urinary tract infections (cystitis), prescribe nitrofurantoin 100 mg twice daily for 5 days. 1

Treatment Regimen for Acute Uncomplicated Cystitis

  • Standard dosing is nitrofurantoin 100 mg orally twice daily for 5 days, which achieves clinical and microbiological cure rates of 90-92% 1
  • This regimen is recommended by the Infectious Diseases Society of America and European Society of Clinical Microbiology and Infectious Diseases as highly effective first-line therapy 1
  • The World Health Organization classifies nitrofurantoin as an Access (A) category antibiotic for lower urinary tract infections, making it a preferred first-line agent 2

Evidence on Treatment Duration

While 5-day courses are the current standard, the evidence base shows some variation:

  • Avoid single-dose therapy: Single-dose antibiotics show significantly higher rates of bacteriological persistence compared to 3-6 day courses (RR 2.01) or 7-14 day courses (RR 1.93) 2
  • 3-day courses may be effective in select populations: Studies in children demonstrated equivalent efficacy between 3-day and 10-day courses for presumed lower UTI (relapse rates 7.7% vs 8.7%, not statistically different) 3
  • However, 5-day courses are recommended over 3-day courses based on current guideline consensus, as direct comparative evidence supporting 3-day nitrofurantoin courses in adults is limited 1, 4

Critical Contraindications and Limitations

Do not use nitrofurantoin for pyelonephritis or systemic infections - it does not achieve adequate serum concentrations for upper tract or systemic disease 1

Contraindicated in the last trimester of pregnancy due to risk of hemolytic anemia in the newborn 1

For pyelonephritis (upper UTI), use ciprofloxacin for mild-to-moderate cases or ceftriaxone/cefotaxime for severe cases instead 2

Prophylactic Dosing for Recurrent UTI

For women with recurrent UTIs, daily prophylactic dosing of nitrofurantoin can be prescribed after discussing risks and benefits 2:

  • Daily dosing is the most tested prophylactic schedule 2
  • Duration typically ranges from 6-12 months with periodic assessment 2
  • Post-coital prophylaxis (single dose after intercourse) is effective for women with UTIs temporally related to sexual activity 2

Safety Profile

Serious adverse events are extremely rare but must be discussed:

  • Pulmonary toxicity risk: 0.001% 2
  • Hepatic toxicity risk: 0.0003% 2
  • Common minor effects include gastrointestinal disturbances and skin rash 2

Advantages in Resistant Infections

Nitrofurantoin maintains effectiveness against multidrug-resistant pathogens:

  • Active against vancomycin-resistant enterococci (VRE) 1
  • Microbiological cure rates of 68-92% against various uropathogens, including resistant strains 1
  • Lacks R-factor resistance patterns seen with newer antimicrobials 5

References

Guideline

Nitrofurantoin Effectiveness in Treating Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Nitrofurantoin: what is the evidence for current UK guidance?

The Journal of antimicrobial chemotherapy, 2023

Research

Nitrofurantoin: an update.

Obstetrical & gynecological survey, 1989

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.